Who are ondansetron and dyclonine hydrochloride's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ondansetron-and-dyclonine-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ondansetron and dyclonine hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ondansetron and dyclonine hydrochloride (ondansetron and dyclonine hydrochloride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist with local anesthetic. Area: Gastroenterology; Oncology; Perioperative Medicine.

marketed 5-HT3 receptor antagonist with local anesthetic 5-HT3 receptor; local anesthetic (sodium channel blockade) Gastroenterology; Oncology; Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

ondansetron and dyclonine hydrochloride (ondansetron and dyclonine hydrochloride) — Peking Union Medical College Hospital. Ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting, while dyclonine hydrochloride provides local anesthetic action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ondansetron and dyclonine hydrochloride TARGET	ondansetron and dyclonine hydrochloride	Peking Union Medical College Hospital	marketed	5-HT3 receptor antagonist with local anesthetic	5-HT3 receptor; local anesthetic (sodium channel blockade)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist with local anesthetic class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ondansetron and dyclonine hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/ondansetron-and-dyclonine-hydrochloride. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab